FindTrial
Sign In

Un estudio de seguridad y eficacia del travoprost 0.004% en comparacion con latanoprost 0.005% en pacientes con glaucoma cronico de angulo cerrado.

DOUBLE-BLIND STUDY OF PARALLEL GROUPS, PRIMARY TREATMENT, TWELVE WEEKS OF DURATION, ON THE SAFETY AND EFFECTIVENESS OF TRAVOPROST 0.004% COMPARED WITH LATANOPROST 0.005% IN PATIENTS WITH NON-STRAINED ANGLE CHRONIC GLAUCOMA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-029-02
Enrollment
40
Registered
2002-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Travoprost 0,004% Type of group
Travoprost 0.004% is administered once a day (night) for 12 weeks. Group name:Latanoprost 0,005% Type of group
Latanoprost 0.005% is administered once a day (night) for 12 weeks.

Sponsors

ALCON RESEARCH LTD.,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients of any race and either sex with chronic angle-closure glaucoma.

Exclusion criteria

Exclusion criteria: Women of childbearing age. Ocular mechanical trauma prior. History of infection or eye inflammation within the last three months. Any abnormality that does not allow tonometry of applanation of any eye.

Design outcomes

Primary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Secondary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Countries

Australia, Taiwan, United States

Outcome results

None listed

Source: REPEC (via WHO ICTRP)